Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Rockwell Medical's Debt-to-EBITDA or its related term are showing as below:
RMTI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.82 Med: -1.01 Max: 4.58
Current: -6.82
During the past 13 years, the highest Debt-to-EBITDA Ratio of Rockwell Medical was 4.58. The lowest was -6.82. And the median was -1.01.
RMTI's Debt-to-EBITDA is ranked worse than 100% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs RMTI: -6.82
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Rockwell Medical Debt-to-EBITDA Related Terms
Rockwell Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RMTI vs BTAI, MRMD, TXMD: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Rockwell Medical (RMTI) has a Debt-to-EBITDA of -4.43 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rockwell Medical. According to the industry distribution chart, Rockwell Medical ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Rockwell Medical's Debt-to-EBITDA too high?
Rockwell Medical's current Debt-to-EBITDA is -4.43. Based on the distribution chart, Rockwell Medical ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rockwell Medical has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Debt-to-EBITDA compare to BTAI and MRMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #999999 out of 682 companies for Debt-to-EBITDA. This places Rockwell Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Rockwell Medical. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current Debt-to-EBITDA is -4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (RMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.74, compared to a current price of $7.16 — trading 18.1% below its estimated fair value. The current Debt-to-EBITDA is -4.43. Rockwell Medical's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Rockwell Medical (RMTI), the current Debt-to-EBITDA is -4.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (RMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued.
The current stock price of $7.16 is trading 18.1% below its estimated GF Value™ of $8.74.
GuruFocus considers Rockwell Medical to be Modestly Undervalued.
Key valuation signals for RMTI:
Debt-to-EBITDA: -4.43
GF Value™: $8.74 vs. price of $7.16 (18.1% below fair value)
No single metric tells the full story. See the RMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
46GF Score
Get the complete analysis for RMTI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTI has been successfully added to your 
